CPRX - FDA approves Catalyst Santhera drug Agamree for Duchenne MD
2023-10-26 16:34:53 ET
More on Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils
- Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Call Transcript
- Catalyst gets FDA review for higher dose of Firdapse for rare neuromuscular disorder
- Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing
- Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals
For further details see:
FDA approves Catalyst, Santhera drug Agamree for Duchenne MD